FOXO4-DRI is a pharmacological peptide that competitively binds to p53 and drives senescent cells into the apoptotic process, thereby greatly ameliorating the side effects of aging and chemotherapy.
Foxo4-dri (FOXO4-derived Peptide Inhibitor) FOXO4 is a cell-permeable peptide antagonist designed specifically to block the interaction between FOXO4 (Forkhead Box O4) and P53, a key tumor suppressor protein. This interaction plays an important role in cellular senescence and tumorigenesis. Therefore, the development of FOXO4DRI provides a new strategy for anti-aging and anti-cancer therapy.
Interaction between FOXO4 and P53
FOXO4 and P53 are important transcription factors in cell biology, where they play key roles in regulating the cell cycle, apoptosis, DNA repair, and metabolism. However, when cells age, FOXO4 will bind to P53, which will inhibit the normal functions of P53, including the ability to induce cell death. This inhibition may promote the accumulation of senescent cells, thereby increasing the risk of tumors.
Mechanism of action of FOXO4-DRI
Foxo4-dri competitively blocks the combination of FOXO4 and P53, mimicking the structure of the combined site of FOXO4 and P53. When FOXO4 is occupied by FOXO4-DRI, P53 can restore its normal transcriptional activity and apoptosis inducing ability. Thus, FOXO4-DRI can induce apoptosis in senescent cells that are inhibited by FOXO4-P53 interaction, thereby eliminating these cells that may contribute to disease.
Anti-aging and anti-cancer potential
FOXO4-DRI is considered to have significant anti-aging and anticancer potential due to its ability to induce apoptosis in senescent cells. FOXO4-DRI helps to delay the aging process and reduce the risk of age-related diseases. FOXO4-DRI can also be used as a novel anticancer agent to inhibit tumor growth and spread by promoting tumor cell apoptosis, while due to the close association between senescent cells and tumorigenesis.
Post time: Aug-22-2024